A New Drug Trial Is Targeting a Key Parkinson’s Gene

Imagine a future where your Parkinson’s treatment is tailored to your genes — not just your symptoms. That’s exactly what a new global trial is aiming to do. In June 2025, biotech company Neuron23 announced two big milestones: they raised over $96 million to develop new Parkinson’s treatments, and they officially dosed their first patient in a major international clinical trial called NEULARK. The trial focuses on a new drug called NEU-411, designed specifically for people whose Parkinson’s is driven by changes in a gene called LRRK2. So what does that mean for you or someone you care about who has Parkinson’s? Let’s break it down. 🔍 What’s NEU-411 — and What’s the Big Idea? NEU-411 is a type of drug called a LRRK2 inhibitor. It’s designed to dial down the activity of a particular brain enzyme (linked to the LRRK2 gene) that researchers believe plays a key role in how Parkinson’s develops and progresses. This isn’t just another symptom-management drug. NEU-411 aims to slow or change the actual disease process — a major step beyond today’s treatments, which mostly help with movement and daily function but don’t stop PD from getting worse. Even better, NEU-411 is taken as a once-daily pill that reaches deep into the brain, where it needs to work. 🧪 What’s Happening in the Trial? The trial is called NEULARK, and it’s now underway across global sites. About 150 people with early-stage Parkinson’s will take part. To be eligible, participants must have a form of Parkinson’s called LRRK2-driven PD. Participants will take either NEU-411 or a placebo (dummy pill) for 52 weeks — and their symptoms will be tracked in detail, using smartphones with special software that monitors motor issues like tremors and stiffness, as well as non-motor symptoms like mood and thinking. This is one of the first major clinical trials to use a precision medicine approach in Parkinson’s, meaning researchers are selecting people based on their genetics to find out who benefits most from this targeted treatment. 🧬 What Is LRRK2 and Do I Have It? The LRRK2 gene is one of the most well-studied genetic links to Parkinson’s. Around 2% of all people with Parkinson’s have a direct mutation in LRRK2. But scientists now believe that up to 30% of people with PD may have subtle changes (called SNPs) that cause overactivity of the LRRK2 pathway — even if they don’t have a family history or a full-blown mutation. That means this treatment could potentially help a much wider group of people than previously thought. If you want to find out if you might be eligible, the trial partner Sano Genetics is offering free saliva testing kits for people with PD. You can find more at neulark.com. 💡 Why This Trial Matters Most Parkinson’s medications today only treat the symptoms. They don’t slow the disease itself. This trial could change that. If NEU-411 proves effective, it would be one of the first truly targeted therapies — something that not only improves symptoms but also alters the course of the disease, at least for some. It also represents a shift toward personalised medicine in Parkinson’s — where your treatment is based on your genetic makeup, not just a generic checklist. That’s a huge deal, especially for those who’ve felt stuck with the same treatment options for years. ⚖️ What’s the Catch? This is still a Phase 2 trial, meaning it’s early days. We won’t see the full results until 2027. It also won’t be the right drug for everyone — just those with LRRK2-driven Parkinson’s, which is why the genetic screening is so important. And, like any new drug, NEU-411 will need to prove it’s both effective and safe over the long term. 🧠 Big Picture: A Hopeful Step Toward Precision Parkinson’s Care Whether or not you’re a candidate for this trial, it marks a hopeful moment for the Parkinson’s community. It’s a sign that big money, serious science, and cutting-edge technology are coming together to find better solutions — and that researchers are starting to treat Parkinson’s not as one single disease, but as a collection of overlapping conditions, many of which may respond to different types of care. If NEU-411 works, it could be the beginning of a new chapter — one where Parkinson’s treatment is more personalised, more precise, and maybe, one day, even preventative.